The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa

  • Yasuhiro Ikeda
  • Toshio Hisatomi
  • Noriko Yoshida
  • Shoji Notomi
  • Yusuke Murakami
  • Hiroshi Enaida
  • Tatsuro Ishibashi
Retinal Disorders

Abstract

Background

Cystoid macular edema (CME) is one of the common complications of retinitis pigmentosa (RP), and is responsible for patient complications such as blurred and reduced visual acuity and for subsequent atrophic changes in the fovea. The objective of this work was to evaluate the clinical efficacy of a topical dorzolamide (a carbonic anhydrase inhibitor) in CME associated with RP.

Methods

Sixteen eyes of nine patients with CME secondary to typical forms of RP were included in the study. Baseline visual acuity, visual field, and optical coherence tomography (OCT) measurements were obtained for all patients. All patients used 1% dorzolamide three times daily in each eye. Patients underwent follow-up exams at 1, 3, and 6 months after treatment. The response to treatment was monitored by visual acuity and visual field measurement testing using the Humphrey Field Analyzer (HFA: the central 10-2 Program); in addition, foveal thickness was measured by OCT. Evaluation of macular sensitivity calculated by HFA as the average of 12 central points.

Results

Thirteen (81.3%) of 16 eyes showed a clear decrease in retinal thickness after treatment. Evaluation of macular sensitivity, calculated by HFA as the average of 12 central points (with the exception of foveal point data, showed an improvement of more than 1.0 dB in nine (56.3%) of 16 eyes. Moreover, both the mean deviation value and macular sensitivity were significantly improved. No severe side-effects were seen in any of the patients examined.

Conclusions

The results demonstrated that a topical dorzolamide is effective for the treatment of CME in patients with RP, and that the positive treatment effects last for up to 6 months.

Keywords

Retinitis pigmentosa Cystoid macular edema A topical carbonic anhydrase inhibitor Macular sensitivity 

Notes

Acknowledgements

KN International provided language assistance. This work was supported in part by a Grant-in-Aid (to YI) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (#20791259). None of the authors has any financial interests to disclose.

Competing interests

None

References

  1. 1.
    Pruett RC (1983) Retinitis pigmentosa: clinical observations and correlations. Trans Am Ophthalmol Soc 81:693–735PubMedGoogle Scholar
  2. 2.
    Berson EL (1993) Retinitis pigmentosa. The Friedenwald lecture. Invest Ophthalmol Vis Sci 34:1659–1676PubMedGoogle Scholar
  3. 3.
    Grover S, Fishman GA, Anderson RJ, Alexander KR, Derlacki DJ (1997) Rate of visual field loss in retinitis pigmentosa. Ophthalmology 104:460–465PubMedGoogle Scholar
  4. 4.
    Fishman GA, Maggiano JM, Fishman M (1977) Foveal lesions seen in retinitis pigmentosa. Arch Ophthalmol 95:1993–1996PubMedCrossRefGoogle Scholar
  5. 5.
    Hirakawa H, Iijima H, Gohdo T, Tsukahara S (1999) Optical coherence tomography of cystoid macular edema associated with retinitis pigmentosa. Am J Ophthalmol 128:185–191PubMedCrossRefGoogle Scholar
  6. 6.
    Hajali M, Fishman GA, Anderson RJ (2008) The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography. Br J Ophthalmol 92:1065–1068PubMedCrossRefGoogle Scholar
  7. 7.
    Sandberg MA, Brockhurst RJ, Gaudio AR, Berson EL (2005) The association between visual acuity and central retinal thickness in retinitis pigmentosa. Invest Ophthalmol Vis Sci 46:3349–3354PubMedCrossRefGoogle Scholar
  8. 8.
    Sandberg MA, Brockhurst RJ, Gaudio AR, Berson EL (2008) Visual acuity is related to parafoveal retinal thickness in patients with retinitis pigmentosa and macular cysts. Invest Ophthalmol Vis Sci 49:4568–7452PubMedCrossRefGoogle Scholar
  9. 9.
    Cox SN, Hay E, Bird AC (1988) Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol 106:1190–1195PubMedCrossRefGoogle Scholar
  10. 10.
    Fishman GA, Gilbert LD, Fiscella RG, Kimura AE, Jampol LM (1989) Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol 107:1445–1452PubMedCrossRefGoogle Scholar
  11. 11.
    Ozdemir H, Karacorlu M, Karacorlu S (2005) Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmol Scand 83:248–251PubMedCrossRefGoogle Scholar
  12. 12.
    García-Arumí J, Martinez V, Sararols L, Corcostegui B (2003) Vitreoretinal surgery for cystoid macular edema associated with retinitis pigmentosa. Ophthalmology 110:1164–1169PubMedCrossRefGoogle Scholar
  13. 13.
    Grover S, Apushkin MA, Fishman GA (2006) Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 141:850–858PubMedCrossRefGoogle Scholar
  14. 14.
    Fishman GA, Apushkin MA (2007) Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol 91:743–745PubMedCrossRefGoogle Scholar
  15. 15.
    Ito Y, Terasaki H, Takahashi A, Yamakoshi T, Kondo M, Nakamura M (2005) Dissociated optic nerve fiber layer appearance after internal limiting membrane peeling for idiopathic macular holes. Ophthalmology 112:1415–1420PubMedCrossRefGoogle Scholar
  16. 16.
    Heckenlively JR, Jordan BL, Aptsiauri N (1999) Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 127:565–573PubMedCrossRefGoogle Scholar
  17. 17.
    Vinores SA, Küchle M, Derevjanik NL, Henderer JD, Mahlow J, Green WR, Campochiaro PA (1995) Blood–retinal barrier breakdown in retinitis pigmentosa: light and electron microscopic immunolocalization. Histol Histopathol 10:913–923PubMedGoogle Scholar
  18. 18.
    Wolfensberger TJ (1999) The role of carbonic anhydrase inhibitors in the management of macular edema. Doc Ophthalmol 97:387–397PubMedCrossRefGoogle Scholar
  19. 19.
    Moldow B, Sander B, Larsen M, Engler C, Li B, Rosenberg T, Lund-Andersen H (1998) The effect of acetazolamide on passive and active transport of fluorescein across the blood–retina barrier in retinitis pigmentosa complicated by macular oedema. Graefes Arch Clin Exp Ophthalmol 236:881–889PubMedCrossRefGoogle Scholar
  20. 20.
    Moldow B, Sander B, Larsen M, Lund-Andersen H (1999) Effects of acetazolamide on passive and active transport of fluorescein across the normal BRB. Invest Ophthalmol Vis Sci 40:1770–1775PubMedGoogle Scholar
  21. 21.
    Apushkin MA, Fishman GA, Grover S, Janowicz MJ (2007) Rebound of cystoid macular edema with continued use of acetazolamide in patients with retinitis pigmentosa. Retina 27:1112–1128PubMedCrossRefGoogle Scholar
  22. 22.
    Cheeks L, Green K (1986) Distribution of a steroid antagonist in the eye following topical administration. Curr Eye Res 5:705–709PubMedCrossRefGoogle Scholar
  23. 23.
    Conroy CW (1997) Sulfonamides do not reach the retina in therapeutic amounts after topical application to the cornea. J Ocul Pharmacol Ther 13:465–472PubMedCrossRefGoogle Scholar
  24. 24.
    Mizuno K, Koide T, Saito N, Fujii M, Nagahara M, Tomidokoro A, Tamaki Y, Araie M (2002) Topical nipradilol: effects on optic nerve head circulation in humans and periocular distribution in monkeys. Invest Ophthalmol Vis Sci 43:3243–3250PubMedGoogle Scholar
  25. 25.
    Chung H, Hwang JU, Kim JG, Yoon YH (2006) Optical coherence tomography in the diagnosis and monitoring of cystoid macular edema in patients with retinitis pigmentosa. Retina 26:922–927PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Yasuhiro Ikeda
    • 1
  • Toshio Hisatomi
    • 1
  • Noriko Yoshida
    • 1
  • Shoji Notomi
    • 1
  • Yusuke Murakami
    • 1
  • Hiroshi Enaida
    • 1
  • Tatsuro Ishibashi
    • 1
  1. 1.Department of Ophthalmology, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan

Personalised recommendations